Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon ...

Second Stride operates three farms in the Louisville area that has helped find new homes for roughly 2,000 thoroughbreds after their racing career.

The increasing prevalence of myopia is a global health concern, with high myopia increasing the risk of vision damage. This necessitates the use of artificial intelligence (AI) for early diagnosis, ...

Regardless of duration of treatment, children who stopped wearing dual-focus contact lenses for myopia control maintained prior treatment gains, with eye growth rates similar to those of untreated ...

HALT spectacle lenses can significantly reduce myopic progression independently from, or as a supplement to, low-dose atropine.

Dual-focus contact lenses appeared effective in high myopia in teenagers and young adults, according to a study published in ...